Home - ABOUT CSTONE - Milestones
Milestones
  • Company Profile
  • Management Team
  • SAB
  • Vision & Mission
  • Milestones
  • Investor
  • Contact Us
  • 2016
    March, 2016 - CStone commences Series A-1 to A-3 rounds of financing and in aggregate raises approximately US$150 million.
    April, 2016 - CStone founded in Suzhou.
    2017
    October, 2017 - CStone Suzhou Translational Medicine Research Center established and commences operations.
    October, 2017 - China's first full-length and fully human PD-L1 monoclonal antibody (CS1001) enters Phase I clinical trial with the dosing of the first patient in China.
    2018
    May, 2018 - CStone completes Series B round of financing, raising in aggregate approximately US$262 million, the largest of Series B financing in China's biopharmaceutical sector at the time.
    June, 2018 - CStone and Blueprint Medicines Corp. (NASDAQ:BPMC) enter into an exclusive collaboration and license agreement regarding the clinical development and commercialization of avapritinib CS3007 (BLU-285), CS3008 (BLU-554) and CS3009 (BLU-667), as mono-therapies or in combination with other therapies, in Greater China including Hong Kong, Macau and Taiwan.
    June, 2018 - CStone and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) enter into an exclusive partnership and license agreement regarding the clinical development and commercialization of ivosidenib (TIBSOVO®; AG-120), as a mono-therapy or in combination with other therapies, in Greater China including Hong Kong, Macau and Taiwan.
    July, 2018 - The U.S. FDA approves TIBSOVO® (ivosidenib), a product developed by CStone's partner Agios Pharmaceuticals, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
    December, 2018 - The clinical research program for “the Category 1 new biologic drug injectable CS1001, a recombinant anti-PD-L1 fully human monoclonal antibody” receives special national support as a “13th Five-Year Plan” major new drug technology research project.
    2019
    February 26, 2019 - CStone becomes publicly listed on the Main Board of the Hong Kong Stock Exchange, stock code: 2616.
    March, 2019 - Three internationally renowned oncology experts appointed to CStone's Scientific Advisory Board.
    May, 2019 - CStone and Numab Therapeutics AG enter into an exclusive collaboration and license agreement regarding the clinical development and commercialization of ND021 in Mainland China, Hong Kong, Macau, Taiwan, South Korea and Singapore.
    June, 2019 - CStone submits a New Drug Application (NDA) in Taiwan for TIBSOVO® (ivosidenib), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.